JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

177 / 348 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 23:33 UTC

Kuumad aktsiad

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28. apr 2026, 23:24 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28. apr 2026, 22:46 UTC

Tulu

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28. apr 2026, 22:37 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28. apr 2026, 22:15 UTC

Tulu

Uudisväärsed sündmused

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28. apr 2026, 23:19 UTC

Market Talk

Tulu

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28. apr 2026, 23:09 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28. apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees One Rate Rise to 4% in Benign Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28. apr 2026, 22:51 UTC

Tulu

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28. apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28. apr 2026, 22:40 UTC

Market Talk

Uudisväärsed sündmused

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28. apr 2026, 22:32 UTC

Tulu

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28. apr 2026, 22:22 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28. apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28. apr 2026, 22:07 UTC

Market Talk

Uudisväärsed sündmused

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

177 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.